 | , - |
 | Room A709, Paris Dauphine University |
The regulation of drug prices is largely structured by a scissor effect between two major challenges: access to therapeutic innovation for all and controlling healthcare expenditure. Although it accounts for "only" 16% of healthcare spending, the drugs budget is in the region of €32 billion. At the same time, innovations in "targeted" therapies are undergoing considerable development, and are the focus of most investment by both Big Pharma and innovative companies.
Ways forward are being explored. The most recent CSIS (Conseil Stratégique des Industries de Santé - Strategic Council for the Healthcare Industries) provided an opportunity to formulate commitments to change policy and practice. In addition, new drug evaluation methodologies based on the collection and use of real-life data represent a profound change in impact assessment methods.
The aim of this breakfast is to discuss these issues from the perspective of three players with very different approaches to the subject: a representative of the pharmaceutical industry, the chairman of the committee responsible for setting prices, and a health economist who will provide an international view of the issues and practices involved.
Speakers
- Eric BASEILHAC | Directeur des affaires économiques et internationales, Leem
- Brigitte DORMONT | Directrice du Laboratoire d’Economie et de gestion des Organisations de Santé et Titulaire de la Chaire Santé, Université Paris-Dauphine – PSL
- Maurice-Pierre PLANEL | Président, Comité économique des produits de santé
The debate will be led byKarim HATEM | Senior Partner, Ylios
